-
-
-
-
-
-
-
Regeneron's Otarmeni gains EMA review for genetic hearing loss
-
-
-
-
-
-
-
Regeneron Pharma (REGN) PT Lowered to $730 at BMO Capital Following LAG-3 Miss
-
-
-
-
-
-
-
Regeneron Pharma (REGN) PT Raised to $995 at Guggenheim
-
-
-
-
-
-
-
Piper Sandler on Regeneron Pharma (REGN): 'Channel Checks Point to Branded Anti-VEGF Expansion'
-
-
-
-
-
-
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
-
-
-
-
-
-
FDA approves EYLEA HD for extended dosing up to 20 weeks
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Regeneron Pharma (REGN) following Ph3 study results
-
429,440 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

